Product Images Pregabalin

Not available.*

Each capsule contains 25 mg pregabalin. Usual Dosage: See accompanying prescribing information. Dispense in tight (USP), child-resistant containers. Store at 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) See USP Controlled Room Temperature. Pharmacist: Dispense the enclosed Medication Guide to each patient. NDC 14445-173-90 Pregabalin Capsules - Rx ONLY 90 Capsules. Manufactured by: INDOCO REMEDIES LTD. Visit the website for more details.*

Each capsule contains 50 mg of pregabalin. The usual dosage information can be found in the accompanying prescribing information. These capsules should be dispensed in tight, child-resistant containers and stored at 25°C (77°F), with excursions permitted to 15-30°C (59-86°F). The medication guide should be dispensed to each patient. Manufactured by Indoco Remedies Ltd. in Goa, India.*

This text appears to be a label or package insert for a medication. It includes information such as the GTIN, expiration date, lot number, and a unique identifier code. The medication seems to be in capsule form with a recommended dosage. It emphasizes that the capsules should be stored in child-resistant containers. The text also mentions a medication guide for each patient. The address provided on the label is from Verna Industrial Area in Goa, India. Additionally, there is a code number indicated as GO/DRUGS/318.*

Not available.*

This document seems to include data related to responder rates for different doses or treatments. The rates are in percentages, with values of 40.6%, 29.1%, and 22.6% being mentioned. There is also a reference to a placebo treatment at doses of 2.5 mg/kg/day and 10 mg/kg/day. However, the meaning or context of the data is not entirely clear.*

Not available.*

This text provides data on the percentage of patients who experienced improvement in pain levels compared to baseline. The chart displays a percentage improvement in pain levels with a specific mention of 10%. The information seems to be part of a wider analysis or study.*

This text provides information on the percentage of subjects who improved on pregabalin and placebo from baseline to week 12 in a study. It shows the percentage improvement at different time points for each group.*

This data presents the percentage of subjects who showed improvement over a given period (from baseline to week 16 BOCF) when treated with Pregabalin and Placebo. The graph shows that 100% of subjects with Pregabalin improved, whereas Placebo shows a lower improvement percentage.*

Not available.*

Percent of Patients Improved: This text provides information on the improvement in pain levels for patients taking Pregabalin at different dosages and frequencies. The data appears to compare the effectiveness of Pregabalin 100mg taken multiple times a day versus 0mg taken three times a day, with a reference to "Placata." Additional details may be included in the text, such as the percentage of improvement in pain from baseline, although the information is not fully clear due to the output.*

This text provides data on the percent of patients improved with different daily doses of Pregabalin as well as a placebo. The chart shows a comparison of the percentage improvement in pain from baseline for each dosage level. The highest improvement appears to be at a dose of 600mg daily.*

This text provides medical information related to a patient, including the weight, serum creatinine level, and reference range for female patients. It seems to be part of a clinical report or medical record.*